BOCH
Blue Owl Capital Holdings Portfolio holdings
AUM $310M
1-Year Return
6.98%
This Quarter Return
+29.19%
1 Year Return
+6.98%
3 Year Return
+59.66%
5 Year Return
–
10 Year Return
–
AUM
$501M
AUM Growth
+$82.2M
(+20%)
Cap. Flow
-$101M
Cap. Flow
% of AUM
-20.09%
Top 10 Holdings %
Top 10 Hldgs %
69.75%
Holding
49
New
6
Increased
15
Reduced
6
Closed
4
Top Buys
| 1 |
enGene Holdings
ENGN
|
+$20.8M |
| 2 |
EverCommerce
EVCM
|
+$15.5M |
| 3 |
Sagimet Biosciences
SGMT
|
+$7.15M |
| 4 |
Larimar Therapeutics
LRMR
|
+$4.4M |
| 5 |
Aquestive Therapeutics
AQST
|
+$3.73M |
Top Sells
| 1 |
Toast
TOST
|
+$139M |
| 2 |
Keros Therapeutics
KROS
|
+$11.9M |
| 3 |
Cullinan Oncology
CGEM
|
+$8.43M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$6.63M |
| 5 |
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
|
+$6.17M |
Sector Composition
| 1 | Healthcare | 66.92% |
| 2 | Financials | 17.24% |
| 3 | Technology | 14.42% |
| 4 | Industrials | 0.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Robinhood
HOOD
$104B
| $54M | 10.78% |
4,237,409
| – | – |
|
|
2
Cullinan Oncology
CGEM
$375M
| $49.8M | 9.96% |
2,924,842
-495,000
| -14% | -$8.43M |
|
3
Pliant Therapeutics
PLRX
$93.9M
| $44.8M | 8.94% |
3,004,199
| – | – |
|
|
4
enGene Holdings
ENGN
$305M
| $41.7M | 8.33% |
2,461,350
+1,226,590
| +99% | +$20.8M |
|
5
Tourmaline Bio
TRML
$1.22B
| $32M | 6.39% |
1,447,401
+115,099
| +9% | +$2.54M |
|
6
Blue Owl Capital
OBDC
$7B
| $31.5M | 6.28% |
2,045,070
| – | – |
|
7
Klaviyo
KVYO
$9.88B
| $30.5M | 6.1% |
1,198,270
| – | – |
|
|
8
Larimar Therapeutics
LRMR
$342M
| $30.3M | 6.06% |
3,994,468
+580,000
| +17% | +$4.4M |
|
|
SLRN
9
DELISTED
ACELYRIN
SLRN
| $19.1M | 3.81% |
2,826,028
+533,038
| +23% | +$3.6M |
|
|
10
EverCommerce
EVCM
$2.15B
| $15.5M | 3.09% |
+1,641,929
| New | +$15.5M |
|
11
Repare Therapeutics
RPTX
$74.7M
| $14.7M | 2.94% |
3,122,499
| – | – |
|
12
Ultragenyx Pharmaceutical
RARE
$2.84B
| $12.5M | 2.5% |
268,238
+5,000
| +2% | +$233K |
|
|
13
Keros Therapeutics
KROS
$632M
| $11.4M | 2.28% |
172,633
-180,000
| -51% | -$11.9M |
|
|
INZY
14
DELISTED
Inozyme Pharma
INZY
| $9.73M | 1.94% |
1,270,027
| – | – |
|
15
Disc Medicine
IRON
$2.08B
| $9.67M | 1.93% |
155,260
+15,000
| +11% | +$934K |
|
|
16
Sagimet Biosciences
SGMT
$202M
| $9.07M | 1.81% |
1,673,877
+1,318,500
| +371% | +$7.15M |
|
|
17
Toast
TOST
$23.3B
| $8.04M | 1.61% |
322,578
-5,567,696
| -95% | -$139M |
|
|
ETWO
18
DELISTED
E2open Parent Holdings
ETWO
| $7.33M | 1.46% |
1,650,943
| – | – |
|
19
Mineralys Therapeutics
MLYS
$2.81B
| $6.99M | 1.4% |
541,080
-27,299
| -5% | -$352K |
|
20
Compass Therapeutics
CMPX
$633M
| $5.6M | 1.12% |
2,829,712
| – | – |
|
|
IMA
21
ImageneBio, Inc. Common Stock
IMA
$100M
| $5.53M | 1.1% |
324,260
+161,459
| +99% | +$2.75M |
|
22
MoonLake Immunotherapeutics
MLTX
$3.38B
| $5.02M | 1% |
100,000
+35,000
| +54% | +$1.76M |
|
23
Dell
DELL
$85.8B
| $4.71M | 0.94% |
41,245
+6,154
| +18% | +$702K |
|
|
OMGA
24
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $3.85M | 0.77% |
1,055,882
| – | – |
|
|
25
Aquestive Therapeutics
AQST
$589M
| $3.73M | 0.74% |
+875,000
| New | +$3.73M |
|